Searching over 5,500,000 cases.

Buy This Entire Record For $7.95

Official citation and/or docket number and footnotes (if any) for this case available with purchase.

Learn more about what you receive with purchase of this case.


United States District Court, Northern District of Illinois, Eastern Division

March 4, 2003


The opinion of the court was delivered by: James B. Moran, Senior Judge, United States District Court


Plaintiff Anil K. Bidani M.D. (Bidani) brings this qui tam action pursuant to the False Claims Act, 31 U.S.C. § 3729. Defendants Edmund S. Lewis (Lewis). American Medical Supply Corporation (AMS), and Circle Medical Management Corporation (CMM) move for summary judgment. For the following reasons, their motion is denied.


The facts and procedural history of this case are contained in various prior opinions. Bidani v. Lewis et al., 1998 WL 1820753 (12/29/98); Bidani v. Lewis et al., 1999 WL 163503 (3/12/99); Bidani v. Lewis et al., 2001 WL 32868 (1/12/01); Bidani v. Lewis et al., 2001 WL 747524 (6/29/01); Bidani v. Lewis et al., 2001 WL 1609377 (12/14/01). Relevant to this motion, defendant AMS, wholly-owned by defendant Lewis, is a corporation engaged in the business of selling medical supplies. AMS paid Abbot Laboratories and Baxter Healthcare Corporation to provide supplies and equipment to dialysis patients and then submitted claims to Medicare for reimbursement. Abbot and Baxter gave AMS discounts and rebates from the list prices it charged for supplies. AMS did not report receiving these discounts in its claims to Medicare.

One count of the complaint remains. Bidani alleges that the supply discounts received by defendants were illegal kickbacks under the Social Security Act, 42 U.S.C. § 1320a-7b. He asserts that the alleged violation of the anti-kickback statute was material in the government's treatment of the Medicare reimbursement claims and as such the submissions violate the False Claims Act, 31 U.S.C. § 3729, et seq.


Summary judgment is appropriate only if there are no genuine issues of material fact and the moving party is entitled to judgment as a matter of law. Celotex Corp. v. Catrett, 477 U.S. 317, 322-23 (1986). We draw all inferences and view all admissible evidence in the light most favorable to the non-moving party. Anderson v. Liberty Lobby, Inc., 477 U.S. 242, 255 (1986).

During the relevant time period, Medicare's anti-kickback statute (AKS) prohibited receiving remuneration for purchasing supplies that are reimbursable. 42 U.S.C § 1320a-7b(h)(1). Discounts are considered remuneration unless "the reduction in price is properly disclosed and appropriately reflected in the costs claimed or charges made by the provider." 42 U.S.C. § 1320a-7b(b)(3)(A). The False Claims Act (WA) prohibits knowingly presenting a false or fraudulent claim for payment or approval to the government 31 U.S.C. § 3729(a)(1).

Bidani's FCA claim is premised on a theory of implied certification. Under this theory "a claim made in contravention of statutory or regulatory requirements may be deemed `false' under the WA in cases where the defendant's certification of compliance with the statutes and regulations in question is a condition of receiving funds from the Government." Mikes v. Straus, 84 F. Supp.2d 427, 434 (S.D.N.Y. 1999), citing Luckey v. Baxter Healthcare Corp., 2 F. Supp.2d 1034, 1045 (N.D.Ill. 1998), aff'd 183 F.3d 730, 732 (7th Cir. 1999), cert. denied, 528 U.S. 1038. To succeed, Bidani must show that the alleged AKS violation was material to the government's treatment of defendants' Medicare claims. Luckey., 183 F.3d at 732. Defendants move for summary judgment on the grounds that Bidani has failed to offer evidence to satisfy this materiality requirement.*fn1

Courts have split over whether the FCA materiality element requires a showing of outcome materiality (that a falsehood or misrepresentation affects the government's ultimate decision to remit fund) or claim materiality (that the misrepresentation is material to a defendant's claim of right). See generally U.S. v. Southland Management Corp.; 288 F.3d 665, 675-6 (5th Cir. 2002). In addressing this issue the Seventh Circuit leans toward an outcome materiality definition, stating that an omission must be "material to the government's buying decision." Luckey, 183 F.3d at 732. The courts in this district have followed suit. Sharp v. Consolidated Medical Transport, Inc., 2001 WL 1035720, *8 (N.D.Ill. 2001) (must show that the goal was to convince the government to pay claims it would not otherwise have paid); King v. F.E. Moran Inc., 2002 WL 2003219 *10 (N.D.Ill. 2002) (the issue is whether the government would have paid or even allowed defendant to keep its contract if it had known of the alleged fraud).

But even knowing that the more stringent outcome materiality test applies, we are still left with the task of flushing out what evidence would suffice to satisfy the element. Since there was no disclosure, how the government would have treated defendants' individual claims is a hypothetical question. So we turn instead to the inquiries of whether compliance with the AKS was so important to the Medicare reimbursement process or so central to Medicare reimbursement agreements that compliance with the AKS was a condition of reimbursement so that failure to disclose non-compliance resulted in wrongful payments.

In support of their motion, defendants submit commentary for 1992 amendments to the Medicare program setting caps for reimbursement for the supplies at issue in this case. See 42 C.F.R. part 414 (effective 12/17/1992). The commentary discusses findings by the Office of Inspector General for the Department of Health & Human Services (OIG) and the Health Care Financing Administration (HCFA), which recognize that the government does not have access to suppliers costs and that real costs are often lower than the set caps. Defendants assert that these comments show that failure to disclose the discounts was not material since the government payment amount would have been the same regardless of the actual cost of the supplies.*fn2 But defendants misread the allegations against them. They are not accused merely of failing to report discounts that lowered their actual supply costs, but rather of submitting claims for supplies for which they received illegal kickbacks. It is the statutory violation that is the basis for the FCA claim, not overpayment.

The government has entered a statement of interest in this case, arguing that since AKS is a critical provision of the Medicare statute, compliance with it is material to the government's treatment of claims for reimbursement. We agree. The AKS criminalizes receiving remuneration intended to affect decisions to purchase supplies for which payment may be made under Medicare. 42 U.S.C § 1320a-7b(b)(1). Those convicted under the AKS they are barred from participating in the federal health care program. 42 U.S.C. § 1320a-7(a)(1). Compliance with the AKS is thus central to the reimbursement plan of Medicare. To state otherwise would be to allow participation and reimbursement for supplies purchased illegally only because the claimant had the luck of not being caught and convicted in the first place. Reimbursing a claimant for the supplies would put the government in the position of funding illegal kickbacks after the fact. This situation exemplifies the "inducing wrongful payment" test for determining materiality contemplated in Luckey, supra.

Having found that the alleged AKS violation is material to the government's treatment of defendants' reimbursement claims, we leave to a trier of fact the remaining elements of the FCA claim, including the question of whether the discounts violate the AKS.*fn3


For the above reasons, defendants' motion for summary judgment is denied.

Buy This Entire Record For $7.95

Official citation and/or docket number and footnotes (if any) for this case available with purchase.

Learn more about what you receive with purchase of this case.